Name | RS-601 |
---|---|
Synonyms |
4-[4-(5,5,6,6,6-Pentafluoro-1-{[(4-fluorophenyl)sulfonyl]amino}hexyl)phenyl]butanoic acid
4-(4-(5,5,6,6,6-pentafluoro-1-(4-fluorobenzene-sulfonamido)hexyl)phenyl)butyric acid Benzenebutanoic acid, 4-[5,5,6,6,6-pentafluoro-1-[[(4-fluorophenyl)sulfonyl]amino]hexyl]- |
Description | RS-601 is a novel leukotriene D4 (LTD4)/thromboxane A2 (TxA2) dual receptor antagonist, with antiasthmatic activities. |
---|---|
Related Catalog | |
Target |
LTD4 TXA2 Receptor |
In Vivo | RS-601 (1-10 mg/kg) clearly inhibits the bronchoconstriction induced by intravenous administration of U-46619 and LTD4 in a dose-dependent fashion in guinea pigs. RS-1452 (10 mg/kg) significantly inhibits U-46619-induced bronchoconstriction, respectively. RS-601 significantly inhibits the late-phase response and LPS-induced AHR at a dose of 10 mg/kg, but does not affect biphasic bronchial responses. RS-601 (3 and 10 mg/kg) also clearly inhibits the AHR[1]. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 563.3±60.0 °C at 760 mmHg |
Molecular Formula | C22H23F6NO4S |
Molecular Weight | 511.478 |
Flash Point | 294.5±32.9 °C |
Exact Mass | 511.125183 |
LogP | 4.84 |
Vapour Pressure | 0.0±1.6 mmHg at 25°C |
Index of Refraction | 1.511 |
Storage condition | 2-8℃ |